JP2024513999A5 - - Google Patents

Info

Publication number
JP2024513999A5
JP2024513999A5 JP2023563063A JP2023563063A JP2024513999A5 JP 2024513999 A5 JP2024513999 A5 JP 2024513999A5 JP 2023563063 A JP2023563063 A JP 2023563063A JP 2023563063 A JP2023563063 A JP 2023563063A JP 2024513999 A5 JP2024513999 A5 JP 2024513999A5
Authority
JP
Japan
Prior art keywords
mrna
vaccine according
respiratory viral
antigenic polypeptide
encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513999A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024669 external-priority patent/WO2022221440A1/en
Publication of JP2024513999A publication Critical patent/JP2024513999A/ja
Publication of JP2024513999A5 publication Critical patent/JP2024513999A5/ja
Pending legal-status Critical Current

Links

JP2023563063A 2021-04-14 2022-04-13 インフルエンザ-コロナウイルス組み合わせワクチン Pending JP2024513999A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163175007P 2021-04-14 2021-04-14
US63/175,007 2021-04-14
US202163242346P 2021-09-09 2021-09-09
US63/242,346 2021-09-09
PCT/US2022/024669 WO2022221440A1 (en) 2021-04-14 2022-04-13 Influenza-coronavirus combination vaccines

Publications (2)

Publication Number Publication Date
JP2024513999A JP2024513999A (ja) 2024-03-27
JP2024513999A5 true JP2024513999A5 (cg-RX-API-DMAC10.html) 2025-04-21

Family

ID=81579694

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563063A Pending JP2024513999A (ja) 2021-04-14 2022-04-13 インフルエンザ-コロナウイルス組み合わせワクチン

Country Status (5)

Country Link
US (1) US20240226277A1 (cg-RX-API-DMAC10.html)
EP (1) EP4322994A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024513999A (cg-RX-API-DMAC10.html)
AU (1) AU2022258463A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022221440A1 (cg-RX-API-DMAC10.html)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. CONCATEMEE peptide epitope RNAs
DE20164728T1 (de) 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
US12128113B2 (en) 2016-05-18 2024-10-29 Modernatx, Inc. Polynucleotides encoding JAGGED1 for the treatment of Alagille syndrome
SG11201901941YA (en) 2016-09-14 2019-04-29 Modernatx Inc High purity rna compositions and methods for preparation thereof
MA46766A (fr) 2016-11-11 2019-09-18 Modernatx Inc Vaccin antigrippal
WO2018170270A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Varicella zoster virus (vzv) vaccine
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
MA48047A (fr) 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
MA49421A (fr) 2017-06-15 2020-04-22 Modernatx Inc Formulations d'arn
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. HPLC ANALYTICAL PROCESSES
MX2020002348A (es) 2017-08-31 2020-10-08 Modernatx Inc Métodos de elaboración de nanopartículas lipídicas.
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
US12151029B2 (en) 2018-09-19 2024-11-26 Modernatx, Inc. PEG lipids and uses thereof
CN112996854B (zh) 2018-09-19 2024-08-30 摩登纳特斯有限公司 高纯度peg脂质和其用途
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CN113939282A (zh) 2019-01-31 2022-01-14 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
MX2021011031A (es) 2019-03-11 2021-12-10 Modernatx Inc Proceso de transcripción in vitro en lotes alimentados.
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
US12529047B1 (en) 2021-12-21 2026-01-20 Modernatx, Inc. mRNA quantification methods
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
EP4604995A1 (en) * 2022-10-17 2025-08-27 BioNTech SE Combination vaccines against coronavirus infection, influenza infection, and/or rsv infection
KR20260021825A (ko) * 2023-05-10 2026-02-13 세퀴러스 인코포레이티드 복합 백신
US20260083835A1 (en) * 2024-09-25 2026-03-26 The Catholic University Of America Modular bacteriophage t4 nanoparticle platform enables rapid design of dual covid-19-flu mucosal vaccines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE291925T1 (de) 2001-06-05 2005-04-15 Curevac Gmbh Stabilisierte mrna mit erhöhtem g/c-gehalt und optimierter codon usage für die gentherapie
US9012219B2 (en) 2005-08-23 2015-04-21 The Trustees Of The University Of Pennsylvania RNA preparations comprising purified modified RNA for reprogramming cells
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
JP2010531640A (ja) 2007-06-29 2010-09-30 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション 毒性化合物の分解方法
DK2205618T3 (en) 2007-09-26 2017-02-20 Intrexon Corp SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION
SG10201408164XA (en) 2007-12-11 2015-01-29 Scripps Research Inst Compositions and methods related to mrna translational enhancer elements
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
EA201492055A1 (ru) 2012-06-08 2015-11-30 Шир Хьюман Дженетик Терапис, Инк. ИНГАЛЯЦИОННАЯ ДОСТАВКА мРНК В НЕЛЕГОЧНЫЕ КЛЕТКИ-МИШЕНИ
ES2967701T3 (es) 2013-03-15 2024-05-03 Translate Bio Inc Mejora sinergística de la entrega de ácidos nucleicos mediante formulaciones mezcladas
SG10201801428RA (en) 2013-08-21 2018-03-28 Curevac Ag Method for increasing expression of rna-encoded proteins
WO2015062738A1 (en) 2013-11-01 2015-05-07 Curevac Gmbh Modified rna with decreased immunostimulatory properties
CA2927254C (en) 2013-12-30 2023-10-24 Curevac Ag Artificial nucleic acid molecules
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
DE20164728T1 (de) * 2015-10-22 2021-09-30 Modernatx, Inc. Impfstoffe gegen atemwegsvirus
EP3405579A1 (en) 2016-01-22 2018-11-28 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2019036682A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. RNA VARIANTS POLYMERASE
MX2021010075A (es) 2019-02-20 2021-12-10 Modernatx Inc Variantes de arn polimerasa para la formacion de casquetes cotranscripcionales.
JP2023527175A (ja) * 2020-05-21 2023-06-27 ヴァクセス・テクノロジーズ,インコーポレーテッド ワクチン放出のための組成物およびデバイスならびにそれらの使用
WO2021239880A1 (en) * 2020-05-29 2021-12-02 Curevac Ag Nucleic acid based combination vaccines
GB2596820A (en) * 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
CN112546211A (zh) * 2020-10-23 2021-03-26 嘉晨西海(杭州)生物技术有限公司 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法

Similar Documents

Publication Publication Date Title
JP2024514182A5 (cg-RX-API-DMAC10.html)
Serradell et al. Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins
JP5331340B2 (ja) インフルエンザウィルスワクチン組成物、及びその使用方法
JP7817257B2 (ja) mRNAワクチンを送達するための脂質ナノ粒子
TW202233232A (zh) 遞送mRNA疫苗的脂質奈米顆粒
JP2024503698A5 (cg-RX-API-DMAC10.html)
Wohlbold et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice
US6780421B1 (en) Adjuvant for a vaccine composition
Garçon et al. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach
JP2011504486A5 (cg-RX-API-DMAC10.html)
Gupta et al. A review of the role of CpG oligodeoxynucleotides as toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases
Ibañez et al. M2e-displaying virus-like particles with associated RNA promote T helper 1 type adaptive immunity against influenza A
JP6185548B2 (ja) インフルエンザワクチンの製造方法
JP2009539965A5 (cg-RX-API-DMAC10.html)
JP2017035093A5 (cg-RX-API-DMAC10.html)
Fotouhi et al. Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus
TW201427686A (zh) 改良之疫苗組成物及使用方法
Lau et al. The contribution of systemic and pulmonary immune effectors to vaccine-induced protection from H5N1 influenza virus infection
JP2015500854A5 (cg-RX-API-DMAC10.html)
JP2009514839A5 (cg-RX-API-DMAC10.html)
Chaparian et al. A virion-based combination vaccine protects against influenza and SARS-CoV-2 disease in mice
JP2024015475A (ja) コロナウイルスワクチン
JP2024150687A (ja) アジュバントおよび該アジュバントを含むワクチン
Zhang et al. DNA-based influenza vaccines as immunoprophylactic agents toward universality
Lim et al. RNA-dependent assembly of chimeric antigen nanoparticles as an efficient H5N1 pre-pandemic vaccine platform